SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
July 26, 2024 12:18 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $342.00 price target on Biogen (NASDAQ: BIIB)
The analyst comments "The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for BIIB/Eisais Leqembi, stating that the slowing of cognitive decline in treated patients does not outweigh the safety risks... More
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
July 26, 2024 10:40 AM EDTPiper Sandler analyst Christopher Raymond lowered the price target on Biogen (NASDAQ: BIIB) to $307.00 (from $313.00) while maintaining a Overweight rating.
The analyst comments "Conclusion: Remain OW on BIIB shares despite news this morning that the EMAs Committee for Medicinal Products for Human... More
Biogen (BIIB) PT Lowered to $282 at RBC Capital
July 26, 2024 10:10 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $282.00 (from $303.00) while maintaining a Outperform rating.
The analyst comments "Our analysis suggests a 20% historical success rate for drugs CHMP re-examines; looking at prior examples over the past 10 years, we... More
Sage Therapeutics stock sinks after drug study failed
July 24, 2024 8:15 AM EDTSAGE Therapeutics (NASDAQ: SAGE) stock price dropped significantly pre-market Wednesday after the company, alongside partner Biogen, announced disappointing results from a late-stage clinical trial for its drug SAGE-324 (BIIB124) for essential tremor (ET).
The Phase 2 KINETIC 2 study failed to meet its primary endpoint, which measured improvement in upper limb tremors. Additionally, no... More
SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
July 24, 2024 7:43 AM EDTSAGE Therapeutics (NASDAQ: SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor- No statistically significant differences were demonstrated between any dose of SAGE-324 and... More